We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Orders Supernus to Stop Misleading Promotion of Oxtellar XR
FDA Orders Supernus to Stop Misleading Promotion of Oxtellar XR
The FDA’s Office of Prescription Drug Promotion is ordering Supernus Pharmaceutical to stop making misleading claims about the use and risks of Oxtellar XR.